An interventional study of Glafkos drainage device in Glaucoma, sponsored by Rheon Medical SA. Status unknown at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-09-18.
Sponsored by Rheon Medical SA · Not applicable, Interventional, and Prevention
This will be a prospective, descriptive, mono-center, non-comparative study. A sample of 30 patients who satisfy entry criteria is estimated to be appropriate to provide safety and performance data for this study.
The objectives of the study are to verify the performance and safety of the Glafkos adjustable glaucoma drainage device system. Performance will be measured assessing the possibility to adjust the intra-ocular pressure post-operatively. Safety will be measured by the incidence and severity of adverse events.
The Glafkos device will be implanted in combination with a seton tube. The implant is placed under a scleral flap, in a manner analogous to the ex-Press device (Alcon). The distal end of the draining tube is linked to a seton draining tube, which is linked to a plate placed under the extraocular muscles, creating a filtering space at the orbit (filtering bleb).
1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.
This study's planned enrollment of 30 is below the median of 65 across 1,272 interventional studies indexed under Glaucoma.
Browse Glaucoma studies →Rheon Medical SA is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Device: Glafkos drainage device
Also known as: eyeWatch
Number and type of SADE per patient.
Time frame: 24 months
IOP measurement
IOP reduced by ≥ 20% or IOP \< 21 mmHg, and no IOP \< 5 mmHg on two consecutive visits after 3 months.
Time frame: 24 months
Comprehensive biomicroscopy examination
Anterior and posterior segments examination using a slit-lamp biomicroscope to evaluate the condition of the cornea (epithelium, stroma, endothelium), the anterior chamber, the iris, the lens, the irido-corneal angle (cf. gonioscopy outcome 9), the vitreous body, retinal and optic nerve anatomy (cf funduscopy outcome 7).
Time frame: day 1, day 7, day 14, day 28, month 2, month 3, month 6, month 12, month 18 and month 24
Assessment of easiness of surgery by surgeon
scale: 0=very easy to 5=very difficult
Time frame: day 0
Assessment of easiness of adjustment
scale: 0=very easy to 5=very difficult
Time frame: for 24 months
Subjective refraction
Assessment of the subjective refraction based on trial and error asking using trial lenses to achieve the best corrected visual acuity
Time frame: day 7, day 14, day 28, month 2, month 3, month 6, month 12, month 18 and month 24
Funduscopy evaluation
indirect funduscopy using a 90D lens to evaluate the optic nerve anatomy (cup to disk ratio measurement) and the retinal structures
Time frame: day 7, day 14, day 28, month 2, month 3, month 6, month 12, month 18 and month 24
Snellen BCVA
Distance (6m) decimal visual acuity after best optical correction was provided
Time frame: day 7, day 14, day 28, month 2, month 3, month 6, month 12, month 18 and month 24
gonioscopy assessment
Irido-corneal angle assessment using the Schaffer grading scale (1-4)
Time frame: day 7 and day 28
This study is status unknown, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rheon Medical SA